IL33 and neoplasm: Accelerated tumor progression through the activation of mannose‐binding lectin (MBL); driving of IL‐33 secretion to recruit and activate Th2 and innate lymphoid cells 2 (ILC2); stimulation of IL‐13 secretion, and ultimately promotion of tumor growth